Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeanette Smith

Physician Assistant New York, NY Physician Assistant

NPI 1043479967 CMS profile 10886890

161 Fort Washington Ave, New York, NY 10032

Open in the dashboard

General payments

$6,915

291 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeanette Smith of New York, NY is reported in the CMS Open Payments database as having received $6,915 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,205 79
2024 General $1,726 69
2023 General $1,586 69
2022 General $194 12
2021 General $1,205 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeanette Smith
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jeanette Smith were reported at $2,205. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jeanette Smith Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,205 $132 $37–$438 $132
2022 $194 $155 $48–$522 $149
2023 $1,586 $167 $52–$557 $160
2024 $1,726 $178 $55–$600 $164
2025 $2,205 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,490 133 payments
  2. AbbVie, Inc. $966 25 payments
  3. Intra-Sana Laboratories $942 42 payments
  4. Madrigal Pharmaceuticals $747 14 payments
  5. Ardelyx, Inc. $477 20 payments
  6. Ironwood Pharmaceuticals, Inc $290 8 payments
  7. Intercept Pharmaceuticals, Inc. $191 10 payments
  8. RedHill Biopharma Inc. $189 11 payments
  9. Ipsen Biopharmaceuticals, Inc $170 4 payments
  10. Phathom Pharmaceuticals, Inc. $117 8 payments
  11. Other $337 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,915 291 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $2,118 110 payments
  2. RELTONE 200 MG $942 42 payments
  3. RELTONE 400 MG $942 42 payments
  4. GLYCATE $847 40 payments
  5. REZDIFFRA $594 11 payments
  6. LINZESS Gastroenterology $584 15 payments
  7. IBSRELA $477 20 payments
  8. CREON $333 12 payments
  9. TRULANCE $333 21 payments
  10. Linzess Gi $306 9 payments
  11. Other $1,521 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,862

Median for Physician Assistant: 241

Drug cost

$260,649

Median for Physician Assistant: $4,110

Branded share of claims

29.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 151 $80,202
Xifaxan Rifaximin Brand 30 $68,920
Trulance Plecanatide Brand 68 $37,195
Dexlansoprazole Dr Dexlansoprazole Brand 248 $36,407
Voquezna Vonoprazan Fumarate Brand 14 $8,447
Movantik Naloxegol Oxalate Brand 17 $6,592
Mesalamine Generic 15 $4,663
Pantoprazole Sodium Generic 864 $4,209
Sucralfate Generic 49 $3,465
Dicyclomine Hcl Generic 380 $2,839

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $459
$459 30 —
LINZESS
  • AbbVie, Inc. $149
  • Ironwood Pharmaceuticals, Inc $39
$188 151 —
RELTONE 200 MG
  • Intra-Sana Laboratories $127
$127 — —
RELTONE 400 MG
  • Intra-Sana Laboratories $127
$127 — —
REZDIFFRA
  • Madrigal Pharmaceuticals $126
$126 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record